Form 4: Agios CFO Jones Reports Equity Transactions

Agios Pharmaceuticals CFO Cecilia Jones reported multiple equity transactions, including the acquisition of common stock through RSU vesting and subsequent sales to cover tax obligations, alongside new RSU and stock option grants.

Summary

• Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals, Inc. (AGIO), reported several transactions related to her equity holdings.
• On March 2, 2026, Jones acquired 2,000 shares of common stock through the exercise/conversion of derivative securities (Restricted Stock Units) at a price of $0.
• Immediately following this acquisition, 594 shares were sold at $28.96 to cover tax withholding obligations related to the vesting of performance share units from a March 1, 2023 agreement.
• Further acquisitions on March 2, 2026, included 5,666 shares, 4,000 shares, and 5,303 shares, all at $0, resulting from additional RSU vesting.
• Corresponding sales to cover tax withholding obligations were 1,681 shares at $28.96 (related to a March 1, 2024 agreement), 1,187 shares at $28.96 (related to a March 1, 2025 agreement), and 1,573 shares at $28.96 (related to a March 1, 2025 agreement).
• Following these transactions, beneficial ownership of common stock by Cecilia Jones was 49,328 shares.
• On March 1, 2026, Jones was granted 14,000 new Restricted Stock Units (RSUs) with a $0 price, which will vest in three equal annual installments beginning March 1, 2027.
• Also on March 1, 2026, Jones was granted 52,000 stock options (right to buy) at an exercise price of $30.23. These options will vest 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, and have an expiration date of March 1, 2036.
• Derivative securities beneficially owned after these transactions include 14,000 Restricted Stock Units and 52,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting ongoing executive compensation and alignment with company performance, without indicating any adverse operational or financial news.

Positives

• New grants of 14,000 Restricted Stock Units and 52,000 stock options indicate continued incentive and alignment of management with shareholder interests.
• The exercise of RSUs and options suggests the underlying stock price is favorable enough to trigger vesting and tax obligations.

Negatives

• Sales of common stock, totaling 594, 1,681, 1,187, and 1,573 shares, occurred to cover tax withholding obligations, which is a common practice but reduces direct ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants and subsequent tax-related sales are standard practices in executive compensation across the biotechnology and pharmaceutical industries. The grants align executive incentives with long-term company performance, a common strategy to retain talent and drive shareholder value.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, including RSUs vesting over multiple years and stock options with a 10-year expiration, is consistent with typical executive compensation packages in the U.S. pharmaceutical sector.
• Similar vesting schedules and option terms are seen at comparable biotech firms like Vertex Pharmaceuticals or Biogen, aiming to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grants of new equity awards align the CFO's interests with long-term shareholder value.
• Shareholders: Tax-related sales are a routine part of compensation and do not signal a lack of confidence.
• Employees: Standard executive compensation practices are maintained.

Next Steps

• Vesting of 14,000 RSUs in three equal annual installments starting March 1, 2027.
• Vesting of 52,000 stock options: 25% on March 1, 2027, and the remaining 75% in 36 equal monthly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and stock options, and subsequent sales to cover tax obligations. Such transactions are pre-scheduled and do not typically reflect a change in the insider's view of the company's prospects or fundamental value. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

Agios Pharmaceuticals, AGIO, Cecilia Jones, CFO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Tax Withholding, Beneficial Ownership